Insulet (Nasdaq:PODD) announced data supporting the use of its Omnipod 5 automated insulin delivery system in young children. Acton, Massachusetts–based Insulet’s Omnipod 5 significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years old with type 1 diabetes over 12 months of use, according to the company. Earlier this year, […]
Real-world data backs Medtronic’s next-gen MiniMed 780G insulin pump
Medtronic (NYSE:MDT) announced positive real-world data supporting its next-generation MiniMed 780G insulin pump system. Results from real-world analyses in Europe and Chile, along with clinical data, were presented by Medtronic at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. According to a news release, the MiniMed 780G advanced hybrid closed loop system, […]
Diabeloop, SOOIL partner on automated insulin delivery technology
Diabeloop announced today that it entered into global development and commercial agreements with insulin delivery technology developer SOOIL. Paris-based Diabeloop, which develops therapeutic artificial intelligence (AI) applied to insulin delivery, and SOOIL will pursue and expand upon technical integration between their platforms, building on cooperation that was initiated in February 2020. According to a news […]
Abbott to develop biowearable for continuous monitoring of glucose, ketone levels
Abbott (NYSE:ABT) announced today that it is developing a new biowearable for continuously monitoring both glucose and ketone levels. The all-in-one sensor has already garnered FDA breakthrough device designation and will be used in pivotal trials in 2023, with regulatory submissions to follow thereafter. Abbott Park, Illinois-based Abbott said in a news release that the […]
Study backs DarioHealth’s digital therapeutics for managing diabetes
DarioHealth (Nasdaq:DRIO) announced today that multiple research studies support its digital therapeutics for diabetes management. New York-based DarioHealth presented the data from the new studies at the American Diabetes Association’s (ADA) 82nd Scientific Sessions in New Orleans. Two of the studies add to DarioHealth’s evidence supporting an integrated approach to managing multiple chronic conditions, while […]
Diabeloop raises $74.9M Series C
Diabeloop announced today that it raised approximately $74.9 million (€70 million) in a Series C financing round. LBO France, a private equity player, led the financing round, while Terumo — with which Diabeloop has partnered since 2020 — also participated in the round. Innovacom joined LBO France and Terumo as new investors, according to a […]
Insulet breaks ground on $200M manufacturing facility in Malaysia
Insulet (Nasdaq:PODD) announced the groundbreaking of its new Omnipod manufacturing facility in Malaysia. Acton, Massachusetts–based Insulet’s Johor Bahru, Malaysia-based manufacturing facility will produce its Omnipod automated insulin delivery system and strengthen the company’s global manufacturing capabilities. The facility will include approximately 400,000 square feet of manufacturing space, with Insulet planning to invest approximately $200 million […]
Beta Bionics looks to reduce ‘cognitive burden’ for those with diabetes with bionic pancreas
Beta Bionics’ iLet bionic pancreas offers insulin therapy without some of the hurdles associated with treating diabetes. Users of insulin pumps may be used to a certain regimen associated with managing their diabetes. That can include carbohydrate counting, setting basal rates and more. Beta Bionics has set out to change that. With the Concord, Massachusetts-based […]
FDA approves Medtronic’s In.Pact 018 drug-coated balloon catheter
Medtronic (NYSE:MDT) announced that it received FDA approval for its In.Pact 018 paclitaxel-coated balloon catheter. Fridley, Minnesota-based Medtronic’s In.Pact 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a drug-coated balloon product, received an indication for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries. According to a news release, […]
Dexcom quashes talk of Insulet merger, says discussions are not ongoing
Dexcom (Nasdaq:DXCM) today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD). Last week, reports circulated saying talks over a potential acquisition were ongoing, with an agreement between the two diabetes technology developers on the horizon in the coming weeks. On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 apiece […]
